Exclusive Summary

• - Off-patent globally and US-registered, enabling fast market entry via distribution with minimal IP barriers
• - Large, durable demand driven by 5-FU–based regimens in CRC plus HD-MTX rescue use across oncology
• - Listed on WHO EML and endorsed by NCCN/ESMO as standard-of-care for 5-FU modulation and HD-MTX rescue
• - Crowded generic field but recurrent shortages; full range of 50/100/200/350/500 mg reduces wastage and fills supply gaps
• - US registration and cGMP credibility plus meaningful cost savings vs brands/levoleucovorin strengthen tender competitiveness